Clostridium difficile, an anaerobic toxigenic bacterium, causes a severe infectious colitis that leads to significant morbidity and mortality worldwide. Both enhanced bacterial toxins and diminished host immune response contribute to symptomatic disease. C. difficile has been a well-established pathogen in North America and Europe for decades, but is just emerging in Asia. This article reviews the epidemiology, microbiology, pathophysiology, and clinical management of C. difficile. Prompt recognition of C. difficile is necessary to implement appropriate infection control practices.
Asia/epidemiology ; Clostridium Infections/*diagnosis/epidemiology/microbiology/*therapy ; Clostridium difficile/genetics/*pathogenicity ; Europe/epidemiology ; Global Health ; Humans ; North America/epidemiology